Brandon J Aubrey

List of Publications by Year
in descending order

18	2,820	687363 13	839539 18
papers	citations	h-index	g-index

18	18	18	5775
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Loss of TRP53 reduces but does not overcome dependency of lymphoma cells on MCL-1. Cell Death and Differentiation, 2022, 29, 1074-1076.	11.2	3
2	MOZ and Meninâ€“MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor. Cancer Discovery, 2022, 12, 1804-1823.	9.4	10
3	Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood, 2021, 137, 2721-2735.	1.4	75
4	Potent Ikaros Degradation By the Cereblon E3 Ligase Modulator CC-92480 Is Effective in Combination with Menin-MLL1 Inhibition in MLL1-Rearranged and NPM1-Mutant AML. Blood, 2021, 138, 208-208.	1.4	2
5	PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia. Blood, 2019, 133, 1729-1741.	1.4	40
6	How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?. Cell Death and Differentiation, 2018, 25, 104-113.	11.2	820
7	Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development. Genes and Development, 2018, 32, 1420-1429.	5.9	29
8	Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature, 2018, 560, 253-257.	27.8	182
9	The BH3-only proteins BIM and PUMA are not critical for the reticulocyte apoptosis caused by loss of the pro-survival protein BCL-XL. Cell Death and Disease, 2017, 8, e2914-e2914.	6.3	18
10	Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis. Cell Reports, 2016, 14, 2337-2347.	6.4	39
11	Tumor-Suppressor Functions of the TP53 Pathway. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026062.	6.2	201
12	RAG-induced DNA lesions activate proapoptotic BIM to suppress lymphomagenesis in p53-deficient mice. Journal of Experimental Medicine, 2016, 213, 2039-2048.	8.5	13
13	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature, 2016, 538, 477-482.	27.8	830
14	BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. Leukemia, 2016, 30, 1531-1541.	7.2	29
15	Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells. Cell Reports, 2016, 14, 1858-1866.	6.4	35
16	An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations InÂVivo. Cell Reports, 2015, 10, 1422-1432.	6.4	337
17	Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes and Development, 2014, 28, 58-70.	5.9	156
18	Progress Findings On a Novel Treatment Strategy Using Prolonged, Low-Dose Cytarabine and Thioguanine in Combination with Peg-Filgrastim for Acute Myeloid Leukaemia in Elderly Patients. Blood, 2012, 120, 3612-3612.	1.4	1